Clinical trial • Phase I • Dermatology
SYX-5219 for Atopic dermatitis
Phase I trial of SYX-5219 for Atopic dermatitis. adaptive. 22 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Atopic dermatitis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 07-07-2025
- First CTIS Authorization Date
- 09-10-2025
Trial design
adaptive Phase I trial across 8 sites in Denmark, Bulgaria, Ireland and others.
- Adaptive
- Yes
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 22
Recruitment
- Planned Sample Size
- 22
- Recruitment Window Months
- 10
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 28
Denmark
- Latest Decision Or Authorization Date
- 27-04-2026
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Sanos A/S
- Department Name
- Dermatology
- Principal Investigator Name
- Nikolai Loft
- Principal Investigator Email
- nikolai.nguyen.loft@regionh.dk
- Contact Person Name
- Nikolai Loft
- Contact Person Email
- nikolai.nguyen.loft@regionh.dk
Bulgaria
- Latest Decision Or Authorization Date
- 21-10-2025
- Number Of Sites
- 2
- Number Of Participants
- 15
Sites
- Site Name
- Medical Center Comac Medical Ltd.
- Department Name
- Skin and Venereal Diseases
- Principal Investigator Name
- Minoo Mehrabian
- Principal Investigator Email
- minoo.mehrabian@comac-medical.com
- Contact Person Name
- Minoo Mehrabian
- Contact Person Email
- minoo.mehrabian@comac-medical.com
- Site Name
- Medical Center Comac Medical Ltd.
- Department Name
- Skin and Venereal Diseases
- Principal Investigator Name
- Minoo Mehrabian
- Principal Investigator Email
- minoo.mehrabian@comac-medical.com
- Contact Person Name
- Minoo Mehrabian
- Contact Person Email
- minoo.mehrabian@comac-medical.com
Ireland
- Latest Decision Or Authorization Date
- 24-10-2025
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- St James's Hospital
- Department Name
- Dermatology
- Principal Investigator Name
- Alan Irvine
- Principal Investigator Email
- irvinea@tcd.ie
- Contact Person Name
- Alan Irvine
- Contact Person Email
- irvinea@tcd.ie
Germany
- Latest Decision Or Authorization Date
- 09-10-2025
- Number Of Sites
- 4
- Number Of Participants
- 6
Sites
- Site Name
- Medical Center - University Of Freiburg
- Department Name
- Dermatology
- Principal Investigator Name
- Kilian Eyerich
- Principal Investigator Email
- kilian.eyerich@uniklinik-freiburg.de
- Contact Person Name
- Kilian Eyerich
- Contact Person Email
- kilian.eyerich@uniklinik-freiburg.de
- Site Name
- University Medical Center Hamburg-Eppendorf
- Department Name
- Dermatology
- Principal Investigator Name
- Matthias Augustin
- Principal Investigator Email
- m.augustin@uke.de
- Contact Person Name
- Matthias Augustin
- Contact Person Email
- m.augustin@uke.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Outpatient Clinic Allergology and Immunology
- Principal Investigator Name
- Margitta Worm
- Principal Investigator Email
- margitta.worm@charite.de
- Contact Person Name
- Margitta Worm
- Contact Person Email
- margitta.worm@charite.de
- Site Name
- Goethe University Frankfurt
- Department Name
- Dermatology
- Principal Investigator Name
- Andreas Pinter
- Principal Investigator Email
- pinter-klifo-ffm@gmx.de
- Contact Person Name
- Andreas Pinter
- Contact Person Email
- pinter-klifo-ffm@gmx.de
Sponsor
Primary sponsor
- Full Name
- Sitryx Therapeutics Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- SYX-5219
- First In Human
- Yes
Related trials
Other published trials that may interest you.